Kyle Hoellger
Sep 29, 2015
Featured

PTAB Sides with Kyle Bass against Celgene

Back in July, Celgene accused Kyle Bass of abusing the inter partes review (IPR) process by short-selling pharmaceutical shares that drop when a petition is filed. Earlier this week, the Patent Trial and Appeal Board (PTAB) dismissed that argument, saying that "Profit is at the heart of nearly ever patent...As such, an economic motive for challenging a patent claim does not itself raise abuse of process standards." The decision was made by a tribunal of six specialized patent judges who also noted that short-selling is "legal and regulated."